Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNOPHYLATE vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SYNOPHYLATE is a bronchodilator that inhibits phosphodiesterase, leading to increased intracellular c AMP. It also acts as an adenosine receptor antagonist and enhances histone deacetylase activity, causing relaxation of bronchial smooth muscle.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of bronchial asthma,Chronic bronchitis,Emphysema,Acute asthmatic exacerbations (off-label)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
400-800 mg orally every 6-8 hours; maximum 3200 mg/day.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life is 3-4 hours in healthy adults, but can be prolonged to 6-8 hours in neonates, cirrhotic patients, or those with heart failure. Clinical context: Requires frequent dosing or extended-release formulations to maintain therapeutic levels.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily hepatic via CYP1A2 and CYP3A4 isoenzymes.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; hepatic metabolism via CYP450 (primarily CYP1A2, CYP3A4) accounts for the remainder. Biliary/fecal excretion of metabolites is minor (<5%).
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Approximately 40-60% bound, primarily to albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
Vd is approximately 0.3-0.7 L/kg, indicating distribution into total body water. Higher Vd in hyperthyroid states, lower in obesity.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral: 80-100% for immediate-release; 90-100% for extended-release. Rectal: 80-90%.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
GFR 30-50 m L/min: 50% of normal dose; GFR <30 m L/min: 25% of normal dose or extend interval to 12-24 hours.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh A: no adjustment; Child-Pugh B: 50% of normal dose; Child-Pugh C: contraindicated or 25% of normal dose with monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
10-15 mg/kg/dose orally every 6-8 hours; maximum 60 mg/kg/day.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Start at 300 mg every 8 hours; titrate cautiously due to increased risk of accumulation and adverse effects.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
None.
None.
Narrow therapeutic index; monitor serum levels. Dosage should be individualized. Avoid excessive caffeine intake.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to xanthine derivatives, active peptic ulcer disease, and seizure disorders.
Hypersensitivity to theophylline or any component of the formulation.
Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) and charcoal-grilled foods, which can reduce theophylline absorption. High-fat meals may increase absorption; take consistently with meals.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
First trimester: Increased risk of neural tube defects and cardiovascular malformations. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal nephrotoxicity. Late third trimester: Risk of premature closure of ductus arteriosus and persistent pulmonary hypertension of the newborn.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Contraindicated during breastfeeding due to high M/P ratio of 3.5, leading to significant infant exposure with potential for adverse effects including renal impairment and gastrointestinal bleeding.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
No dose adjustment required; pharmacokinetics unchanged in pregnancy. However, avoid use after 28 weeks gestation due to fetal renal effects.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
SYNOPHYLATE (theophylline) has a narrow therapeutic index; serum levels should be monitored to maintain 5-15 mcg/m L. Use with caution in patients with heart failure, liver disease, or COPD, as clearance is reduced. Cimetidine, fluoroquinolones, and macrolides increase levels; smoking and carbamazepine decrease levels. Avoid in seizure disorders.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without medical advice, as it affects drug levels.,Inform all healthcare providers you are taking this medication, especially if starting new drugs.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNOPHYLATE vs AEROLATE JR, answered by our medical review team.
SYNOPHYLATE is a Bronchodilator that works by SYNOPHYLATE is a bronchodilator that inhibits phosphodiesterase, leading to increased intracellular c AMP. It also acts as an adenosine receptor antagonist and enhances histone deacetylase activity, causing relaxation of bronchial smooth muscle.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNOPHYLATE and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNOPHYLATE is: 400-800 mg orally every 6-8 hours; maximum 3200 mg/day.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNOPHYLATE and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNOPHYLATE is classified as Category C. First trimester: Increased risk of neural tube defects and cardiovascular malformations. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal n. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.